{
    "title": "R42960",
    "content": "The Hatch-Waxman Act of 1984 reformed patent and food and drug laws to balance innovation and competition in the pharmaceutical industry. Congressional focus has shifted to pharmaceutical patent litigation settlements, where brand-name companies must enforce patents against generic competitors through federal court litigation. This can result in blocking generic competition or opening the market to generic entry. When a drug company enforces its patents against generic competitors in federal court, it can lead to a judgment of infringement blocking competition or a judgment of patent invalidity allowing generic entry. Parties in pharmaceutical patent litigation may settle, with some agreements involving cash payments from the brand-name company to the generic firm in exchange for not challenging the patents or selling a generic version of the drug. These settlements, also known as \"pay-for-delay\" agreements, have varying opinions among commentators. Some believe they stem from the specialized patent litigation procedures established by the Hatch-Waxman Act. The payment flows counterintuitively, from the patent proprietor to the accused infringer, termed as a \"reverse\" payment. Some observers view these settlements as \"pay-for-delay\" agreements. Commentators differ in their views of reverse payment settlements, with some believing they result from specialized patent litigation procedures. Congress has required litigants to notify federal antitrust authorities of pharmaceutical patent settlements since 2003, but has not stipulated substantive standards for assessing the validity of these agreements under antitrust law. Judicial application of general antitrust principles has led to varying outcomes in cases involving reverse payment settlements. The U.S. Supreme Court decision in Federal Trade Commission v. Actavis, Inc. on June 17, 2013, established that reverse payment settlements should be evaluated under the \"rule of reason\" approach. Lower courts now face the challenge of applying this standard to future cases. Legislation before Congress, such as the Preserve Access to Affordable Generics Act (S. 214) and the FAIR Generics Act (S. 504), aims to address reverse payment settlements and reform the Hatch-Waxman Act to reduce incentives for generic firms to settle with brand-name companies. The U.S. Supreme Court decision in Federal Trade Commission v. Actavis, Inc. established that reverse payment settlements should be evaluated under the \"rule of reason\" approach. Legislation like the Preserve Access to Affordable Generics Act (S. 214) and the FAIR Generics Act (S. 504) aims to address reverse payment settlements and reform the Hatch-Waxman Act to reduce incentives for generic firms to settle with brand-name companies. This legislation has not yet been enacted. The report introduces and analyzes innovation and competition policy issues associated with pharmaceutical patent litigation settlements, including the concept of reverse payment settlements and their status under antitrust laws. Inventors must submit patent applications to the USPTO for patent protection. Examiners assess applications for novelty and nonobviousness. Prior art includes existing knowledge accessible to the public. Nonobvious inventions are not readily within ordinary knowledge. To be considered novel, an invention must not be fully anticipated by prior patents or publications. The prior art consists of existing knowledge accessible to the public. If granted, a patent gives the owner the right to exclude others from using the invention for twenty years. This exclusivity allows inventors to profit from their discovery by charging higher prices. The grant of a patent allows inventors to profit from their inventions by charging higher prices and excludes others from using the invention for a limited period. Patent owners must monitor competitors and may need to litigate to enforce their rights. In the pharmaceutical industry, generic competition can lead to lower-cost substitutes for innovative products. However, obtaining FDA approval is necessary before distributing a patented pharmaceutical product to the public, requiring safety and efficacy demonstrations through preclinical and clinical investigations. Prior to the Hatch-Waxman Act, generic drug manufacturers had to file their own New Drug Application (NDA) to sell their products, sometimes relying on published scientific literature for approval. FDA approval is required to distribute patented pharmaceutical products, with safety and efficacy demonstrated through preclinical and clinical investigations. Prior to the Hatch-Waxman Act, generic drug manufacturers had to file their own NDA to sell their products. Some generic manufacturers could rely on published scientific literature for approval, known as a \"paper NDA.\" However, not all generic firms could use this method, and some were required to conduct additional studies by the FDA. This process was seen as costly and time-consuming, leading Congress to enact the Hatch-Waxman Act to streamline the approval of generic drugs. The Hatch-Waxman Act created an expedited pathway for generic drug approval called an Abbreviated New Drug Application (ANDA). This allows generic manufacturers to demonstrate bioequivalence to pioneer drugs without extensive clinical data. ANDAs help avoid costs and delays associated with full NDAs and allow generic drugs to enter the market sooner after patent expiration. The Hatch-Waxman Act created an expedited pathway for generic drug approval through Abbreviated New Drug Applications (ANDAs), allowing generic manufacturers to avoid costs and delays associated with full New Drug Applications (NDAs). This also enables generic drugs to enter the market sooner after patent expiration, with a maximum extension period of five years to compensate brand-name firms for their proprietary data. The Hatch-Waxman Act established procedures to resolve patent disputes between brand-name and generic drug manufacturers. Brand-name firms are compensated for their proprietary data, and generic manufacturers must go through a certification process to market their drugs. The Act also requires NDA applicants to list patents that could be infringed by generic drugs in the \"Orange Book.\" The FDA lists patents in the \"Orange Book\" that could be infringed by generic drugs. Generic drug manufacturers must certify their views on these patents, which are categorized as paragraph I, II, III, or IV certifications. Approval for an ANDA certified under paragraphs I or II is immediate after meeting regulatory requirements. The filing of an ANDA with paragraph III certification requires waiting for patent expiration, while a paragraph IV certification may lead to patent infringement litigation. The Hatch-Waxman Act incentivizes generic drug challenges with a 180-day exclusivity period for the first applicant filing a paragraph IV certification. The Hatch-Waxman Act incentivizes generic drug challenges by providing a 180-day exclusivity period for the first applicant filing a paragraph IV certification. This can lead to potential patent infringement litigation against the applicant. The Act aims to stimulate patent challenges and competition in the pharmaceutical market. Following 2003 amendments to the Hatch-Waxman Act, a first paragraph IV ANDA applicant may lose its entitlement to the 180-day generic exclusivity period due to forfeiture events such as failure to market promptly or obtain FDA approval in a timely manner. The Medicare Prescription Drug, Improvement, and Modernization Act established these forfeiture events to prevent the practice of 'parking' exclusivity periods and force generic manufacturers to market promptly. In patent infringement suits, if the NDA holder proves that the generic product would violate its patents, the court may issue an injunction preventing the generic drug company from marketing the product. Following 2003 amendments to the Hatch-Waxman Act, a first paragraph IV ANDA applicant may lose its entitlement to the 180-day generic exclusivity period due to forfeiture events such as failure to market promptly or obtain FDA approval in a timely manner. In patent infringement suits, if the NDA holder proves that the generic product would violate its patents, the court may issue an injunction preventing the generic drug company from marketing the product. Independent generic firms commonly amend their ANDAs from paragraph IV to paragraph III certifications in response to patent litigation outcomes. The courts may rule in favor of the generic firm, allowing them to launch their product once FDA approval is obtained. This legal situation has led to various cases with different details but a common core issue. Reverse payment settlements in pharmaceutical patent litigation involve a generic firm filing a paragraph IV ANDA, leading to a patent infringement lawsuit. Settlements may result in the generic firm agreeing not to challenge the patent or produce a generic version of the drug in exchange for compensation from the NDA holder. Opinions on these settlements vary, with some viewing them as anticompetitive agreements that restrict output and share patent-based profits. Some commentators view reverse payment settlements in pharmaceutical patent litigation as anticompetitive agreements that restrict output and share patent-based profits. However, others believe that settlements promote settlement, avoid litigation expenses, and resolve disputes in a timely manner. The settlement of litigation serves the goal of resolving disputes peacefully, preserving judicial resources, and involves an exchange of benefits and obligations between rational actors. Certain reverse payment settlements in pharmaceutical patent litigation have allowed for the introduction of generic competition before the patent expires, potentially benefiting consumers. Reverse payment settlements in pharmaceutical patent litigation may allow for generic competition before the patent expires, benefiting consumers. The Hatch-Waxman Act's dispute settlement procedures may promote the use of such settlements. In traditional patent litigation, the accused infringer may compensate the patent proprietor to avoid infringement consequences. The Act's structure alters the balance of risks between the plaintiff-patentee and accused infringer. The Hatch-Waxman Act's unique procedures have led to the emergence of reverse payment settlements in pharmaceutical patent litigation. This allows generic manufacturers to challenge patent validity without facing the risk of significant damages. The Act's structure shifts the balance of risks between patent holders and accused infringers, with limited exposure for generic firms and potential for exclusive sales. Congressional action on pharmaceutical patent litigation settlements remains limited. The Hatch-Waxman Act has led to reverse payment settlements in pharmaceutical patent litigation. Congressional action on these settlements has been limited, but the 2003 Medicare Prescription Drug Act mandated the DOJ and FTC to receive copies of certain patent settlement agreements in the pharmaceutical field. These agreements trigger notification requirements if they relate to specific topics related to brand-name and generic drugs. The Medicare Prescription Drug Act mandated the DOJ and FTC to receive copies of certain patent settlement agreements in the pharmaceutical field. These agreements trigger notification requirements if they relate to specific topics related to brand-name and generic drugs, with exceptions for certain types of agreements. The FTC reported receiving 140 final resolutions of patent disputes in FY2012, with 40 settlements potentially involving pay-for-delay payments. The MMA imposed a filing obligation on certain patent settlements but did not establish substantive standards for their validity. The Medicare Prescription Drug Act mandated the DOJ and FTC to receive copies of patent settlement agreements in the pharmaceutical field. The FTC received 140 final resolutions of patent disputes in FY2012, with 40 settlements potentially involving pay-for-delay payments. The MMA imposed a filing obligation on certain patent settlements but did not establish substantive standards for their validity. Various government and private actors asserted that certain reverse payment settlements violated antitrust laws, leading to different court outcomes based on antitrust law principles. The antitrust laws, including the Sherman Act and Clayton Act, address anti-competitive conduct like reverse payment settlements. Section 1 of the Sherman Act deems contracts restraining trade illegal, with courts assessing reasonableness using the \"rule of reason\" approach. Factors considered include the impact on competition and the nature of the restraint. The \"rule of reason\" approach in antitrust laws requires courts to determine if a practice unreasonably restrains competition by considering various factors. Per se illegality applies to restraints that are conclusively presumed to be unreasonable and illegal without further inquiry. The Supreme Court has established that certain agreements or practices are presumed to be illegal without further inquiry due to their harmful effects on competition. These include price fixing, group boycotts, and market division. Courts may also use a \"quick look\" approach for antitrust cases, requiring defendants to justify their practices to avoid liability. Different courts have varied approaches to reverse payment settlements in pharmaceutical patent litigation. The courts have differing approaches to reverse payment settlements in pharmaceutical patent litigation. The Sixth Circuit held such agreements to be per se invalid, while other circuits ruled them permissible under certain conditions. Reverse payment settlements in pharmaceutical patent litigation have been a topic of debate among courts. While some circuits have deemed them permissible under certain conditions, the Sixth Circuit has classified such agreements as per se invalid. The Eleventh Circuit, for example, ruled that reverse payment settlements are permissible as long as they do not exceed the scope of the patent. In the case of Valley Drug Co. v. Geneva Pharmaceuticals, Inc., the Eleventh Circuit reversed a district court's decision that the agreements constituted a horizontal market allocation that was per se illegal under the Sherman Act. Instead, the Court of Appeals remanded the matter for a determination of whether any part of the agreement went beyond the protections afforded by the brand-name firm's patent. The Court of Appeals reversed the per se illegality standard for reverse payment settlements, remanding the matter for a determination of whether the agreement exceeded patent protections. The Third Circuit rejected the scope of the patent test, stating it restricts antitrust law application and goes against patent litigation and competition policies. The Third Circuit rejected the scope of the patent test, stating it improperly restricts antitrust law application and goes against the policies underlying the Hatch-Waxman Act and Supreme Court precedent on patent litigation and competition. The court believed that the presumption of validity for granted patents was merely a procedural device, not a substantive right of the patent holder. They adopted a \"quick rule of reason\" test that presumed reverse payments were anticompetitive. The Third Circuit rejected the scope of the patent test, adopting a \"quick rule of reason\" test for reverse payment settlements. The Supreme Court held in Federal Trade Commission v. Actavis, Inc. that such settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. Solvay Pharmaceuticals settled a case with generic firms Actavis and Paddock Laboratories over patent infringement of the drug ANDROGEL\u00ae. The FTC charged Solvay Pharmaceuticals and generic firms Actavis and Paddock Laboratories with violating antitrust laws by settling a patent infringement case over ANDROGEL\u00ae. The District Court and Eleventh Circuit rejected the FTC's claims, applying the \"scope of the patent\" standard. The Eleventh Circuit affirmed the District Court's rejection of the FTC's claims against Solvay Pharmaceuticals and generic firms Actavis and Paddock Laboratories over ANDROGEL\u00ae patent infringement settlement. The Supreme Court later reversed the judgment, stating that anticompetitive effects falling within the patent's scope do not immunize agreements from antitrust scrutiny. The Supreme Court reversed a judgment regarding ANDROGEL\u00ae patent infringement settlement, stating that anticompetitive effects within the patent's scope do not exempt agreements from antitrust scrutiny. Justice Breyer reasoned that measuring anticompetitive effects solely against patent law policy is incongruous, and traditional antitrust factors should also be considered. The Supreme Court emphasized that patent-related settlements can violate antitrust laws by considering traditional antitrust factors such as anticompetitive effects, market power, and legal considerations related to patents. The structure of the Hatch-Waxman Act supports subjecting reverse payment settlements to antitrust scrutiny, despite the judicial policy favoring dispute settlement. Justice Breyer highlighted the risk of significant anticompetitive effects from large and unjustified reverse payments. Justice Breyer acknowledged the judicial policy favoring dispute settlement but cited five considerations against near-automatic antitrust immunity for reverse payment settlements. These considerations include the risk of anticompetitive effects, inability to justify large payments, market power from patents, and the ability to settle disputes without such payments. The Supreme Court declined to adopt a presumptively unlawful approach for reverse payment settlements. The Supreme Court declined to adopt a presumptively unlawful approach for reverse payment settlements, stating that antitrust liability must be established using the traditional rule of reason analysis. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented from this decision. The Supreme Court's decision in Actavis rejected a presumptively unlawful approach for reverse payment settlements, emphasizing the need for antitrust liability to be proven through traditional rule of reason analysis. Chief Justice Roberts, Justices Scalia, and Thomas dissented, arguing that such settlements should only be deemed anticompetitive in specific circumstances. This ruling will require pharmaceutical firms to carefully structure and explain their agreements in order to avoid litigation. The Hatch-Waxman Act requires pharmaceutical firms to carefully structure and explain their agreements to settle litigation. The lower courts face the challenge of applying the rule of reason in these cases. Justice Breyer believes antitrust cases under Hatch-Waxman may not always involve detailed examination of patent validity, while the Chief Justice is concerned about the complexity and cost of resolving patent issues. Congress has options to consider, including waiting for further judicial developments after the Actavis decision on reverse payment settlements. One option for Congress is to regulate pharmaceutical patent litigation settlements. Two bills in the 113th Congress address reverse payment settlements, with the Preserve Access to Affordable Generics Act aiming to declare certain agreements as acts of unfair competition. This bill would amend the Federal Trade Commission Act to presume anticompetitive effects and unlawfulness if an ANDA filer receives anything of value and agrees to limit research or sales of the product. The Fair and Immediate Release of Generics Act, S. 504, aims to discourage reverse payment settlements in pharmaceutical patent litigation. It includes provisions granting generic firms the right to share regulatory exclusivity and obligating them to abide by settlement agreements. Brand-name firms would have 45 days to enforce their patents after being notified. The legislation aims to prevent reverse payment settlements in pharmaceutical patent litigation. It would require generic firms to honor settlement agreements and enforce patents within 45 days of notification. The settlement of such litigation is crucial for public health, balancing the development of new medicines by brand-name companies with increased access through generic firms under the Hatch-Waxman Act."
}